Alexis Antonucci

Alexis Antonucci

Auto-generated profile, based on publicly available information

Alexis Antonucci

Department of Internal Medicine, Medical University of South Carolina at Charleston, Charleston, SC

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AAAlexis Antonucci
Alexis Antonucci
ALAlexander R. Lucas
Alexander R. Lucas
JCJuliana Costa
Juliana Costa
SNSam Norton
Sam Norton
PBPeter Brubaker
Peter Brubaker
WHW. Gregory Hundley
W. Gregory Hundley
Introduction: Exercise intolerance is common among cancer patients undergoing active treatments. We conducted a pilot study in patients receiving potentially cardiotoxic therapies to investigate the impact of participation in a 6-month physical activity intervention (PAI) versus a healthy lifestyle education control intervention (HLI) on accelerometer-derived measures of PA (steps/day or minutes of moderate to vigorous PA [MVPA]/week) and whether these measures were associated with submaximal exercise capacity (6-minute walk distance [6MWD]). Methods: Participants with breast cancer or lymphoma (n = 33) were randomized (2:1) into PAI or HLI groups. Exercise training was patient-centered, tailored by treatment and functional status. Objective assessments of PA (steps/day, MVPA/week), and submaximal exercise capacity (6MWD) were completed at baseline, 3-, and 6-months. Descriptive statistics were used to examine changes in PA and 6MWD. T-tests were used to examine differences in 6MWD between groups at 3- and 6-months. Results: At baseline, 27 participants in the PAI (n = 20) and HLI (n = 7) groups who completed baseline and at least 1 follow up visit, had a mean age of 53 (range: 23–76) vs 56 (range: 40–77) years, took on average 8,330 ± 2520 vs 7800 ± 3830 steps/day, did an average of 133 ± 44 vs 109 ± 87 minutes of MVPA/week, and had a mean 6MWD of 496 ± 94 vs 440 ± 18 meters, respectively. At 3- and 6-months there was a 87m and 76m difference in 6MWD by intervention group. A correlation analysis did find significant associations between steps/day (r = 0.51, p = .04) and 6MWD at 3-months. Conclusions: Baseline data indicate that, on average, our study sample was close to meeting the PA guidelines. Unexpectedly, both groups maintained their activity levels up to 3- and 6-months. Submaximal exercise capacity (6MWD) was also maintained (with a clinically meaningful but not statistically significant relative benefit in the PAI) suggesting higher PA levels may associate with reduced exercise intolerance after anthracycline therapy.

19 June 2026 in Clinical Breast Cancer
Verified
Journal Article
Open access
JLJubin K. Lim
Jubin K. Lim
AGAnna E. Gibson
Anna E. Gibson
JHJian He
Jian He
AAAlexis Antonucci
Alexis Antonucci
Harry D. BearHarry D. Bear
Harry D. Bear
Hormone receptor-positive breast cancer (HR + BC) responds well to neoadjuvant endocrine therapy (NET), increasing chances for breast conserving surgery with less toxicity than neoadjuvant chemotherapy (NCT). A National Cancer Database study found that NET use increased by only 0.5% between 2004 and 2012. We investigated the utilization of NET, NCT, and no neoadjuvant therapy (no NT) from 2005 to 2023. We queried the TriNetX database for patients with HR + BC (stages I-III, ER+, PR+, ERBB2-) who underwent mastectomies in the US and evaluated utilization of NET, NCT, or no NT. We trended each use by all ages, age ≤ 50 years, or ≥ 51 years across roughly 5-year increments. NET cases were less than 10 for 2005-2009, and rounding obscured the exact count, so this period was excluded from the trend analysis. The use of NET remained below 1%, while NCT utilization was approximately 11%, and breast conserving surgery was achieved more frequently with NET than NCT (p < .0001). Both therapy types were used more frequently with advanced cancer stage (p < .0001), and NCT use was higher than NET in both age groups (p < .0001). NET and NCT use did not show significant trends when all ages were combined (p = .39). However, age-stratified analyses revealed significant declines in NCT use within each age group, with similar NET patterns and increasing no NT (p < .0001), indicating that overall results may mask weighted subgroup trends. This study highlights underutilization of NET, despite its low toxicity and efficacy in improving patient outcomes. Increased efforts are needed to address this gap and consider NET as an option for HR + BC.